iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma

被引：0
|
作者：
Shapiro, Roman M. [1 ]
Romee, Rizwan [1 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Div Transplantat & Cellular Therapies, Boston, MA 02215 USA
来源：
LANCET | 2025年 / 405卷 / 10473期
关键词：
D O I：
10.1016/S0140-6736(24)02524-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 99
页数：2
相关论文
共 50 条
  • [1] CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment
    Kong, Dasom
    Kwon, Daekee
    Moon, Bokyung
    Kim, Da-Hyun
    Kim, Min-Ji
    Choi, Jungju
    Kang, Kyung-Sun
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [2] CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment
    Kong, Dasom
    Kwon, Daekee
    Moon, Bokyung
    Kim, Da-Hyun
    Kang, Kyung-Sun
    CANCER RESEARCH, 2024, 84 (06)
  • [3] IPSC-derived CAR-NK cells for cancer immunotherapy
    Lin, Xiaotong
    Sun, Yao
    Dong, Xin
    Liu, Zishen
    Sugimura, Ryohichi
    Xie, Guozhu
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 165
  • [4] Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
    Bachanova, Veronika
    Ghobadi, Armin
    Patel, Krish
    Park, Jae H.
    Flinn, Ian W.
    Shah, Prutha
    Wong, Carol
    Bickers, Cara
    Szabo, Peter
    Wong, Lilly
    Valamehr, Bahram
    Atwal, Siminder
    Chu, Yu-Waye
    Elstrom, Rebecca
    Strati, Paolo
    BLOOD, 2021, 138
  • [5] Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
    Bachanova, Veronika
    Cayci, Zuzan
    Lewis, Dixie
    Maakaron, Joseph E.
    Janakiram, Murali
    Bartz, Andersen
    Payne, Steven
    Wong, Carol
    Cooley, Sarah
    Valamehr, Bahram
    Chu, Yu-Waye
    Miller, Jeffrey S.
    BLOOD, 2020, 136
  • [6] Generation of iPSC derived CD19 CAR iNK cells for treatment of autoimmune disorders
    Walsh, Ariane
    Grandolfo, Davide
    Pichery, Melanie
    Turfkruyer-Housson, Mathilde
    Richter, Mandy
    Hublitz, Philip
    Esquerre, Michael
    Bombarde, Oriane
    Holtzinger, Audrey
    Scheel, Andreas
    Wagner, Nadja
    Cernecka, Hana
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [7] CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
    Maus, Marcela V.
    LANCET, 2021, 398 (10299): : 466 - 467
  • [8] CD28-COSTIMULATED CD19 CAR T CELLS FOR PEDIATRIC RELAPSED AND REFRACTORY MATURE B-CELL LYMPHOMA
    Jacoby, Elad
    Adam, Etai
    Abramovich, Alon
    Shapira, Adi
    Hutt, Daphna
    Itzhaki, Orit
    Bielorai, Bella
    Toren, Amos
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 563 - 564
  • [9] Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
    Tong, Chuan
    Zhang, Yajing
    Liu, Yang
    Ji, Xingyu
    Zhang, Wenying
    Guo, Yelei
    Han, Xiao
    Ti, Dongdong
    Dai, Hanren
    Wang, Chunmeng
    Yang, Qingming
    Liu, Wanli
    Wang, Yao
    Wu, Zhiqiang
    Han, Weidong
    BLOOD, 2020, 136 (14) : 1632 - 1644
  • [10] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
    Lihong An
    Yuehui Lin
    Biping Deng
    Zhichao Yin
    Defeng Zhao
    Zhuojun Ling
    Tong Wu
    Yongqiang Zhao
    Alex H. Chang
    Chunrong Tong
    Shuangyou Liu
    BMC Cancer, 22
12345